🟢 Insulet Corporation is trading 4.2% up today on the U.S. rollout of Omnipod 5 upgrades and Libre 3 compatibility

Insulet Corporation is trading 4.21% up now at $149.34 as the company begins the U.S. rollout of major upgrades to its Omnipod 5 Automated Insulin Delivery system.

• The update introduces a lower 100 mg/dL glucose target and full compatibility with Abbott’s FreeStyle Libre 3 sensor, building on previously cleared software enhancements.
• Investors are reacting to renewed product momentum and improved adoption prospects following a recent period of stock underperformance.
• The price action appears to be company-specific, with the stock significantly outperforming a mixed broader market.